Harnessing Your Heartbeat with Ivabradine

Dysautonomia, a complex condition characterized by the autonomic nervous system's dysfunction, can manifest in various challenging symptoms, including rapid heartbeat and palpitations. Ivabradine has emerged as a promising treatment option for managing these cardiovascular symptoms associated with dysautonomia.

Many patients with Long COVID or ME/CFS also experience autonomic dysfunction and symptoms of dysautonomia. Treatment with ivabradine can often provide symptom improvement and a better quality of life.

Dysautonomia patients often struggle with an array of symptoms, but one of the most common and distressing is tachycardia, an abnormally fast heart rate. Ivabradine is designed to target this symptom by reducing the heart rate, which may help:

Ivabradine is FDA-approved for the management of tachycardia associated with stable angina and heart failure not fully managed by beta blockers. Unlike other heart medications that affect blood pressure or contractility, ivabradine's action is heart rate-specific. This targeted approach makes it a valuable off-label option for managing tachycardia commonly seen with postural orthostatic tachycardia syndrome (POTS), especially for patients who may not tolerate traditional beta-blockers. Research suggests it works effectively by targeting the heart's natural pacemaker. Here is a closer look at how ivabradine works in the body.

Ivabradine selectively inhibits the If (often referred to as the “funny”) current in the sinoatrial node, which acts as the heart's natural pacemaker. This specific electrical current plays a crucial role in the initiation and regulation of your heartbeats. By targeting this exact pathway, the medication can help stabilize the heart's rhythm without interfering with other vital cardiovascular functions.

By inhibiting the If current, ivabradine effectively slows the heart’s internal pacemaker speed. This reduces the overall heart rate in a precise and controlled manner, importantly doing so with minimal effects on blood pressure. For patients with autonomic nervous system dysfunction, this means they may achieve a more comfortable resting heart rate without the risk of exacerbating hypotension (low blood pressure) or causing additional dizziness.

A lower, more controlled heart rate allows the heart's chambers to fill up with more blood between beats. As a result, a greater volume of blood is pumped throughout the body with every single heartbeat. By supporting overall cardiac output and efficiency, ivabradine facilitates the better delivery of oxygen-rich blood to the brain and other vital organs. This enhanced circulation may help alleviate common symptoms like severe fatigue and cognitive dysfunction.

For those with dysautonomia, clinical studies show ivabradine can be particularly beneficial in managing symptoms like:

Clinical experience and studies suggest that ivabradine is effective in reducing heart rate and improving symptoms in patients with dysautonomia, though individual responses can vary. Ivabradine is generally well-tolerated, with a safety profile that makes it suitable for long-term use in managing chronic conditions. However, patients should be aware of potential side effects that can include:

Whether you have been living with dysautonomia for years or have only recently received a diagnosis (possibly in connection with Long COVID or ME/CFS), ivabradine is a medication that may help reduce dizziness and improve your quality of life. Ivabradine may help address many of the symptoms, such as fatigue and lightheadedness, that you live with every day. If you are interested in exploring ivabradine as a treatment option, consult with your healthcare provider or visit RTHM to learn how this treatment option can help combat autonomic dysfunction and get you back on the path to better health, as new trials continue to explore these interventions.

Ivabradine is a selective If channel blocker designed for lowering heart rate in order to treat conditions like heart failure (on-label) and is used off-label for many conditions, including postural orthostatic tachycardia syndrome (POTS). Several studies show that ivabradine can improve symptoms in POTS patients by lowering their heart rate without affecting blood pressure. Some key studies include: